New Endpoints, Programs Used for Drug Approvals.
The FDA greenlighted 17 novel cancer agents in 2018, including one with a novel endpoint in a clinical trial and one through an expanded access program. The agency also approved five biosimilars to treat cancer or the side effects of treatment.